Duncan Brown
Overview
Explore the profile of Duncan Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yarlas A, Lovley A, McCausland K, Brown D, Vera-Llonch M, Conceicao I, et al.
Neurol Ther
. 2021 Aug;
10(2):865-886.
PMID: 34355354
Introduction: Patients with hereditary transthyretin amyloidosis associated with polyneuropathy (ATTRv-PN) experience deterioration in health-related quality of life (HRQOL) as the disease progresses. Findings from the randomized placebo-controlled phase III NEURO-TTR...
12.
Yarlas A, Lovley A, Brown D, Kosinski M, Vera-Llonch M
J Neurol
. 2021 Jun;
269(1):323-335.
PMID: 34125267
Objective: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare disease characterized by rapid neuropathic progression. In pivotal studies of gene-silencing treatments, the modified Neuropathy Impairment Score + 7 tests...
13.
Lin X, Yarlas A, Vera-Llonch M, Baranwal N, Biber J, Brown D, et al.
BMC Neurol
. 2021 Feb;
21(1):70.
PMID: 33579211
Background: We aimed to compare neuropathic progression rate between hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and other peripheral neuropathies, including diabetic peripheral neuropathy (DPN) and Charcot-Marie-Tooth disease (CMT). Methods: Literature...
14.
Patton R, Paval D, McDonald J, Brown D, Gallagher I, Skipworth R, et al.
Crit Rev Oncol Hematol
. 2021 Jan;
159:103222.
PMID: 33482344
Background: Development and spread of cancer is linked to the inflammatory response, in which cytokines serve a key role. The inflammatory response may also form the basis for symptoms of...
15.
Powell M, Brown D, Davis C, Walsham J, Calleja P, Nielsen S, et al.
Aust Crit Care
. 2020 May;
33(6):538-545.
PMID: 32409251
Poor-quality patient handover leads to adverse patient outcomes. Consequently, handover has been identified as a national and international priority for preventing patient harm. Risks are exacerbated during transfers of trauma...
16.
Ng B, Cash-Mason T, Wang Y, Seitzer J, Burchard J, Brown D, et al.
Mol Ther Nucleic Acids
. 2019 Mar;
16:194-205.
PMID: 30901578
Clinical application of siRNA-based therapeutics outside of the liver has been hindered by the inefficient delivery of siRNA effector molecules into extra-hepatic organs and cells of interest. To understand the...
17.
Hall C, Norris L, Dixon L, Cook J, Maddocks M, Graham C, et al.
Pilot Feasibility Stud
. 2019 Jan;
4:192.
PMID: 30607255
No abstract available.
18.
Song T, Brown D, Lehnigk U, Corvino F, Lieberman P
Ann Allergy Asthma Immunol
. 2018 Mar;
121(1):132-134.e3.
PMID: 29567356
No abstract available.
19.
Song T, Brown D, Karjalainen M, Lehnigk U, Lieberman P
J Allergy Clin Immunol Pract
. 2018 Feb;
6(5):1559-1567.
PMID: 29408441
Background: Anaphylaxis guidelines recommend prescription of more than 1 epinephrine autoinjector (EAI) for patients at risk. A second epinephrine dose is required in 16% to 36% of patients. Objective: To...
20.
Mihaila R, Ruhela D, Keough E, Cherkaev E, Chang S, Galinski B, et al.
Mol Ther Nucleic Acids
. 2017 Jun;
7:246-255.
PMID: 28624200
Lipid nanoparticles (LNPs) have been used to successfully deliver small interfering RNAs (siRNAs) to target cells in both preclinical and clinical studies and currently are the leading systems for in ...